Neurobiology and treatment of Parkinson's disease.

Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease and is an important cause of chronic disability. Numerous important advances have been made in our understanding of the aetiopathogenesis, pathology and clinical phenomenology of this disease, and these have underpinned advances in symptomatic treatment and the prospect that these might be extended into interventions that will slow progression. It is notable that the continuing characterisation of the downstream biochemical consequences of the genetic causes of PD serves only to reinforce this notion. Progress in the management of PD has continued, particularly in timing of drug initiation and the sequence and combinations in which drugs are used to improve long-term outcome and reduce drug-induced complications. Particular progress has been made in the field of neuroprotection, where novel therapies and clinical trial designs are being tested. This review will focus particularly upon this area.

[1]  Pietro Cortelli,et al.  Homozygous PINK1 C‐terminus mutation causing early‐onset parkinsonism , 2004, Annals of neurology.

[2]  Vesna Sossi,et al.  A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease , 2003, Annals of neurology.

[3]  A. Schapira,et al.  Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells , 2004, Neuropharmacology.

[4]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[5]  E. Tolosa,et al.  End-of-dose Wearing Off in Parkinson Disease: A 9-Question Survey Assessment , 2006, Clinical neuropharmacology.

[6]  R. Nussbaum,et al.  Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1 , 2004, Science.

[7]  A. Schapira,et al.  TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial , 2006, The Lancet Neurology.

[8]  C. Olanow,et al.  Ubiquitin–proteasome system and Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[9]  Pablo Martinez-Martin,et al.  Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; Study using nonmotor symptoms questionnaire in 545 patients , 2007, Movement disorders : official journal of the Movement Disorder Society.

[10]  A Bender,et al.  Creatine supplementation in Parkinson disease: A placebo-controlled randomized pilot trial , 2006, Neurology.

[11]  S. Minoshima,et al.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.

[12]  J. Obeso,et al.  Timing of treatment initiation in Parkinson's disease: A need for reappraisal? , 2006, Annals of neurology.

[13]  D. Nyholm,et al.  Duodenal levodopa infusion in Parkinson's disease – long‐term experience , 2001, Acta neurologica Scandinavica.

[14]  Andrew J. Lees,et al.  Management of Parkinson's disease: An evidence‐based review , 2002, Movement disorders : official journal of the Movement Disorder Society.

[15]  N. Shimizu,et al.  Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: Evidence for variable homozygous deletions in the Parkin gene in affected individuals , 1998, Annals of neurology.

[16]  O Rascol.  A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group , 2000 .

[17]  John Seibyl,et al.  Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. , 2000, JAMA.

[18]  R. Bakay,et al.  Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial , 2008, The Lancet Neurology.

[19]  A. Siderowf,et al.  A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. , 2004, Archives of neurology.

[20]  R. Uitti,et al.  Neurological disorders and services in Saskatchewan--a report based on provincial health care records. , 1988, Neuroepidemiology.

[21]  Werner Poewe,et al.  Evidence‐based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004 , 2005, Movement disorders : official journal of the Movement Disorder Society.

[22]  Joel S Perlmutter,et al.  Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. , 2002, Archives of neurology.

[23]  Richard Gray,et al.  Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients , 2004, BMJ : British Medical Journal.

[24]  M. Hallett,et al.  Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2006, Neurology.

[25]  D. Brooks,et al.  A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. , 2000, The New England journal of medicine.

[26]  T. Iwatsubo,et al.  Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[27]  S. Jick,et al.  Use of antihypertensives and the risk of Parkinson disease , 2008, Neurology.

[28]  Matthew J. Farrer,et al.  Comparison of kindreds with parkinsonism and α‐synuclein genomic multiplications , 2004 .

[29]  C. Marsden,et al.  Oxidative Stress and Parkinson's Disease a , 1996, Annals of the New York Academy of Sciences.

[30]  Yusuke Nakamura,et al.  Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway , 2001, Oncogene.

[31]  G K Wenning,et al.  Apomorphine: An underutilized therapy for Parkinson's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.

[32]  Nir Giladi,et al.  Rotigotine transdermal patch in early Parkinson's disease: A randomized, double‐blind, controlled study versus placebo and ropinirole , 2007, Movement disorders : official journal of the Movement Disorder Society.

[33]  A. Schapira,et al.  Genetic and environmental factors in the cause of Parkinson's disease , 2003, Annals of neurology.

[34]  Anthony H V Schapira,et al.  Treatment options in the modern management of Parkinson disease. , 2007, Archives of neurology.

[35]  W Poewe,et al.  Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial , 2005, The Lancet.

[36]  C. Marsden,et al.  Anatomic and Disease Specificity of NADH CoQ1 Reductase (Complex I) Deficiency in Parkinson's Disease , 1990, Journal of neurochemistry.

[37]  A. Schapira.  Future directions in the treatment of Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[38]  A. Schapira.  Disease modification in Parkinson's disease , 2004, The Lancet Neurology.

[39]  J. Hoenicka,et al.  The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.

[40]  Y. Agid,et al.  A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. , 1999, Human molecular genetics.

[41]  Diana Brahams,et al.  Medicine and the Law , 1983, The Lancet.

[42]  E. Tolosa,et al.  Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study , 2008, The Lancet Neurology.

[43]  E. Hirsch,et al.  Neuronal vulnerability in Parkinson's disease. , 1997, Journal of neural transmission. Supplementum.

[44]  A. Schapira.  Science, medicine, and the future: Parkinson's disease. , 1999, BMJ.

[45]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[46]  R. Palm,et al.  Selegiline slows the progression of the symptoms of Parkinson disease , 2006, Neurology.

[47]  J. Bloch,et al.  Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. , 2000, Science.

[48]  J. Jankovic,et al.  A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease , 2007, Neurology.

[49]  Y. Agid,et al.  G2019S LRRK2 mutation in French and North African families with Parkinson's disease , 2005, Annals of neurology.

[50]  E. Love,et al.  Parkinson's disease and exposure to agricultural work and pesticide chemicals , 1992, Neurology.

[51]  R. Uitti,et al.  Early Onset Parkinson's Disease in Saskatchewan - Environmental Considerations for Etiology , 1986, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[52]  D. Howells,et al.  Effect of Chronic Angiotensin‐Converting Enzyme Inhibition on Striatal Dopamine Content in the MPTP‐Treated Mouse , 1999, Journal of neurochemistry.

[53]  A. Schapira,et al.  Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. , 2004, JAMA.

[54]  Nobutaka Hattori,et al.  Novel PINK1 mutations in early‐onset parkinsonism , 2004, Annals of neurology.

[55]  A. Kupsch,et al.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level , 1996, Brain Research.

[56]  V. Kostic,et al.  Early development of levodopa‐induced dyskinesias and response fluctuations in young‐onset Parkinson's disease , 1991, Neurology.

[57]  K. Chaudhuri,et al.  Non-motor symptoms of Parkinson's disease: diagnosis and management , 2006, The Lancet Neurology.

[58]  Ninds Net-Pd Investigators.  A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. , 2006 .

[59]  A. Schapira.  The importance of LRRK2 mutations in Parkinson disease. , 2006, Archives of neurology.

[60]  A. H. V. Schapira,et al.  MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.

[61]  M. Brin,et al.  Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. , 1993, The New England journal of medicine.

[62]  J. Cooper,et al.  Cyclosporin inhibition of apoptosis induced by mitochondrial complex I toxins , 1998, Brain Research.

[63]  Anthony H V Schapira,et al.  Etiology of Parkinson’s disease , 2006, Neurology.

[64]  E. Hirsch,et al.  Inflammation and dopaminergic neuronal loss in Parkinson's disease: a complex matter , 2003, Experimental Neurology.

[65]  Shinsei Minoshima,et al.  Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase , 2000, Nature Genetics.

[66]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[67]  J. Nutt,et al.  A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. , 2002, Archives of neurology.

[68]  O. Rascol,et al.  Continuous dopamine-receptor stimulation in early Parkinson's disease , 2000, Trends in Neurosciences.

[69]  A. Schapira.  Mitochondria in the aetiology and pathogenesis of Parkinson's disease , 2008, The Lancet Neurology.

[70]  C. Marsden,et al.  Complex I, Iron, and ferritin in Parkinson's disease substantia nigra , 1994, Annals of neurology.

[71]  Richard Grondin,et al.  Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. , 2002, Brain : a journal of neurology.

[72]  Claude Nahmias,et al.  Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study , 2003, Annals of neurology.

[73]  R. Hauser,et al.  Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease , 2008, Nature Medicine.

[74]  Erwan Bezard,et al.  Novel pharmacological targets for the treatment of Parkinson's disease , 2006, Nature Reviews Drug Discovery.

[75]  J. Jankovic,et al.  Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD , 2003, Neurology.

[76]  D. James Surmeier,et al.  ‘Rejuvenation’ protects neurons in mouse models of Parkinson’s disease , 2007, Nature.

[77]  D. Surmeier,et al.  Calcium, ageing, and neuronal vulnerability in Parkinson's disease , 2007, The Lancet Neurology.

[78]  J Q Trojanowski,et al.  Transplantation of embryonic dopamine neurons for severe Parkinson's disease. , 2001, The New England journal of medicine.

[79]  C. Tanner,et al.  Levodopa and the progression of Parkinson's disease. , 2004, The New England journal of medicine.

[80]  Elisabet Englund,et al.  Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation , 2008, Nature Medicine.

[81]  Olaf Riess,et al.  AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease , 1998, Nature Genetics.

[82]  A. Bentivoglio,et al.  PINK1 mutations are associated with sporadic early‐onset parkinsonism , 2004, Annals of neurology.

[83]  C. Marsden,et al.  Mitochondrial Complex I Deficiency in Parkinson's Disease , 1990, Lancet.